Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annieke C G van Baar

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
The American Journal of Gastroenterology|February 19, 2024
Role of the Intestine and Its Gut Microbiota in Metabolic Syndrome and ObesityCeline B E Busch, Jacques J G H M Bergman, Max Nieuwdorp, et al.
BMJ Nutrition, Prevention & Health|August 7, 2025
Long-term effects of duodenal mucosal resurfacing and liraglutide on glycaemic control in patients with type 2 diabetesCeline B E Busch, Julia Rubingh, Annieke C G van Baar, et al.
Gastrointestinal Endoscopy|May 1, 2024
Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human studyCeline B E Busch, Suzanne Meiring, Annieke C G van Baar, et al.
Frontiers in Clinical Diabetes and Healthcare|March 30, 2023
A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot StudySuzanne Meiring, Annieke C G van Baar, Nikolaj Sørensen, et al.
Endoscopy International Open|February 26, 2025
Optimizing duodenal tissue acquisition for mechanistic studies of duodenal ablation in type 2 diabetesCeline B E Busch, Kim van den Hoek, E Andra Neefjes-Borst, et al.
Endocrine Connections|April 20, 2018
Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolitesAnnieke C G van Baar, Andrei Prodan, Camilla D Wahlgren, et al.
Igie : Innovation, Investigation and Insights|February 6, 2026
Durable insulin elimination after duodenal re-cellularization via electroporation therapy combined with glucagon-like peptide-1 receptor agonist in patients with type 2 diabetesCeline B E Busch, Kim van den Hoek, Annieke C G van Baar, et al.
Endoscopy International Open|November 3, 2020
Duodenal mucosal resurfacing: Multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitusAnnieke C G van Baar, Rehan Haidry, Leonardo Rodriguez Grunert, et al.
Gastrointestinal Endoscopy|December 28, 2020
Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility studyAnnieke C G van Baar, Suzanne Meiring, Paul Smeele, et al.
Gastrointestinal Endoscopy|January 27, 2024
Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot studyCeline B E Busch, Suzanne Meiring, Annieke C G van Baar, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
The American Journal of Gastroenterology|February 19, 2024
Role of the Intestine and Its Gut Microbiota in Metabolic Syndrome and ObesityCeline B E Busch, Jacques J G H M Bergman, Max Nieuwdorp, et al.
BMJ Nutrition, Prevention & Health|August 7, 2025
Long-term effects of duodenal mucosal resurfacing and liraglutide on glycaemic control in patients with type 2 diabetesCeline B E Busch, Julia Rubingh, Annieke C G van Baar, et al.
Gastrointestinal Endoscopy|May 1, 2024
Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-in-human studyCeline B E Busch, Suzanne Meiring, Annieke C G van Baar, et al.
Frontiers in Clinical Diabetes and Healthcare|March 30, 2023
A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot StudySuzanne Meiring, Annieke C G van Baar, Nikolaj Sørensen, et al.
Endoscopy International Open|February 26, 2025
Optimizing duodenal tissue acquisition for mechanistic studies of duodenal ablation in type 2 diabetesCeline B E Busch, Kim van den Hoek, E Andra Neefjes-Borst, et al.
Endocrine Connections|April 20, 2018
Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolitesAnnieke C G van Baar, Andrei Prodan, Camilla D Wahlgren, et al.
Igie : Innovation, Investigation and Insights|February 6, 2026
Durable insulin elimination after duodenal re-cellularization via electroporation therapy combined with glucagon-like peptide-1 receptor agonist in patients with type 2 diabetesCeline B E Busch, Kim van den Hoek, Annieke C G van Baar, et al.
Endoscopy International Open|November 3, 2020
Duodenal mucosal resurfacing: Multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitusAnnieke C G van Baar, Rehan Haidry, Leonardo Rodriguez Grunert, et al.
Gastrointestinal Endoscopy|December 28, 2020
Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility studyAnnieke C G van Baar, Suzanne Meiring, Paul Smeele, et al.
Gastrointestinal Endoscopy|January 27, 2024
Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot studyCeline B E Busch, Suzanne Meiring, Annieke C G van Baar, et al.
Pageof 2